Ligand Pharmaceuticals Incorporated (LGND) — Business segments and KPIs
Revenue by business segment and geography for Ligand Pharmaceuticals Incorporated, with year-over-year trends.
FY 2025
| Segment | Revenue | % of total |
|---|---|---|
| Revenue by product | ||
| Royalty | 161M | 32.5% |
| Intangible Royalty Assets | 132.53M | 26.8% |
| Contract Revenue | 66.87M | 13.5% |
| Material Sales, Captisol, Core | 40.21M | 8.1% |
| Royalty, Kyprolis | 35.53M | 7.2% |
| Financial Royalty Assets | 28.47M | 5.8% |
| Royalty, Other | 10.37M | 2.1% |
| License Fees | 6.99M | 1.4% |
| Service | 6.81M | 1.4% |
| Royalty, Evomela | 5.94M | 1.2% |